CVS Health Co. (NYSE: CVS – Get Rating ) has received an average “Moderate Buy” rating from the 21 brokers that currently cover the company, according to MarketBeat. Two analysts have given the stock a Hold recommendation, twelve have issued a Buy recommendation and one has issued a Strong Buy recommendation. Among brokers who updated their stock coverage in the last year, the twelve-month average price target is $119.11.
Several research firms recently weighed in on CVS. Raymond James cut their price target on shares of CVS Health from $120.00 to $115.00 in a research note on Sunday, November 6th. Credit Suisse Group upped their price target on CVS Health from $117.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, November 21st. Evercore ISI upped their price target on CVS Health from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Wednesday, September 7th. Goldman Sachs cut their price target on CVS Health from $128.00 to $113.00 and set a “buy” rating on the company in a report on Thursday, November 3rd. Finally, JPMorgan Chase & Co cut their price target on CVS Health from $130.00 to $125.00 and set an “overweight” rating on the company in a report on Thursday, November 3rd.
CVS Health trades down 0.3%
Shares of CVS opened at $93.19 on the New York Stock Exchange Friday. The company has a market cap of $122.45 billion, a P/E ratio of 39.66, a P/E ratio of 1.45, and a beta of 0.69. CVS Health had a 12-month low of $86.28 and a 12-month high of $111.25. The company has a quick ratio of 0.69, a current ratio of 0.94, and a debt-to-equity ratio of 0.72. The company’s 50-day simple moving average is $97.70 and the 200-day simple moving average is $97.18.
CVS Health (NYSE: CVS – Get Rating ) last reported quarterly earnings results on Wednesday, November 2nd. The pharmacy operator reported EPS of $2.09 for the quarter, beating the consensus estimate of $1.99 by $0.10. The company’s revenue for the quarter was $81.16 billion, compared with analyst estimates of $76.53 billion. CVS Health has a return on equity of 15.56% and a net margin of 1.00%. Sell-side analysts forecast CVS Health to post EPS of 8.62 for the current year.
CVS Health Increases Dividend
The company also recently announced a quarterly dividend, payable on Wednesday, February 1st. Shareholders of record on Friday, January 20 will receive a dividend of $0.605. That’s a boost from CVS Health’s previous quarterly dividend of $0.55. This represents an annualized dividend of $2.42 and a dividend yield of 2.60%. The ex-dividend date is Thursday, January 19. CVS Health has a dividend payout ratio (DPR) of 93.62%.
In other news, Executive Vice President Thomas M. Moriarty sold 137,466 shares of CVS Health in trading on Thursday, Dec. 15. The stock has an average selling price of $98.36 and a total value of $13,521,155.76. Following the sale, the Executive Vice President now directly owns 608,129 shares of company stock, worth approximately $59,815,568.44. The transaction was disclosed in a legal filing with the U.S. Securities and Exchange Commission, which can be accessed at this link. Insiders own 0.69% of the company.
Institutional inflows and outflows
Several hedge funds and other institutional investors recently changed their positions in CVS. SRS Capital Advisors Inc. boosted its position in CVS Health stock by 105.8% in the third quarter. SRS Capital Advisors Inc. now owns 284 shares of the pharmacy operator worth $27,000 after buying an additional 146 shares last quarter. Karp Capital Management Corp purchased $30,000 worth of new positions in CVS Health stock during the third quarter. Coston McIsaac & Partners bought a new position in CVS Health stock worth $34,000 during the second quarter. Moisand Fitzgerald Tamayo LLC boosted its stake in CVS Health by 63.6% in the third quarter. Moisand Fitzgerald Tamayo LLC now owns 368 shares of the pharmacy operator, worth $35,000, after acquiring an additional 143 shares last quarter. Finally, Win Advisors Inc. increased its stake in CVS Health by 60.1% during the second quarter. Win Advisors Inc. now owns 405 shares of the pharmacy operator, worth $38,000, after acquiring an additional 152 shares last quarter. 77.29% of the shares are currently held by institutional investors.
About CVS Health, Inc.
CVS Health Corporation provides health services in the United States. The Company’s Health Care Benefits segment provides traditional, voluntary and consumer-driven health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, healthcare providers, government entities, government-sponsored programs, labor groups, and expats.
This breaking news alert is powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate coverage. This story was reviewed by MarketBeat’s editorial team before publication. Please send any questions or comments about this story to email@example.com.
You’ll want to hear this before you even consider CVS Health.
MarketBeat tracks Wall Street’s highest-rated and top-performing research analysts and the stocks they recommend to clients on a daily basis. MarketBeat has identified five stocks top analysts are quietly telling their clients to buy now before the broader market catches on… and CVS Health isn’t on the list.
Although CVS Health currently has a “Moderate Buy” rating among analysts, the top-rated analysts see these five stocks as better buys.
Check out five stocks here